255723-98-9 Usage
General Description
The chemical (R)-N4-Benzyl-2-(benzyloxymethyl)piperazine is a piperazine derivative with a benzyl group and a benzyloxymethyl group attached to the nitrogen atoms. It is used as a pharmaceutical intermediate in the synthesis of various drugs, including potential antipsychotics and antidepressants. (R)-N4-Benzyl-2-(benzyloxymethyl)piperazine has shown potential in the treatment of various central nervous system disorders, and its molecular structure makes it a promising candidate for further drug development. Additionally,
Check Digit Verification of cas no
The CAS Registry Mumber 255723-98-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,5,7,2 and 3 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 255723-98:
(8*2)+(7*5)+(6*5)+(5*7)+(4*2)+(3*3)+(2*9)+(1*8)=159
159 % 10 = 9
So 255723-98-9 is a valid CAS Registry Number.
InChI:InChI=1/C19H24N2O/c1-3-7-17(8-4-1)13-21-12-11-20-19(14-21)16-22-15-18-9-5-2-6-10-18/h1-10,19-20H,11-16H2/t19-/m1/s1
255723-98-9Relevant articles and documents
Efficient one-pot synthesis of enantiomerically pure: N -protected-α-substituted piperazines from readily available α-amino acids
Jida, Mouhamad,Ballet, Steven
supporting information, p. 1595 - 1599 (2018/02/09)
A new pathway towards enantiomerically pure 3-substituted piperazines, bearing a benzyl protecting group, has been developed in good overall yields (83-92%), starting from commercially available N-protected amino acids. The methodology represents an efficient and simple one-pot procedure, employing a synthetic sequence consisting of an Ugi-4 component reaction, a Boc-deprotection, an intramolecular cyclisation reaction and a final reduction (UDCR). From the benzyl protected precursors, the 2-substituted piperazines bearing a Boc-protecting group could consequently also be obtained via a simple protection and deprotection step of the corresponding piperazines. The practical utility of this methodology was demonstrated for chiral drug synthesis.
